Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which were initially created as antihyperglycemic drugs for type 2 diabetes mellitus, have shown remarkable cardiovascular and renal advantages. Drugs like empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin inhibit glucose reabsorption in the proximal renal tubules, enhancing glycosuria and decreasing plasma glucose. In addition to glycemic control, these agents have impressive cardioprotective actions through enhanced left ventricular function, decreased heart failure hospitalization, and cardiovascular death. By causing natriuresis and osmotic diuresis, they reduce blood pressure and cardiac load, improving overall cardiac efficiency.

Methods: This a prospective and observational study was conducted over a period of six months in OP department and patient relevant data were collected from the patient case sheet in cardiology department at a tertiary care hospital in Telangana . The data collection form was prepared and used. The data collection form contains demographic details like age , gender, socioeconomic factors ,past history ,laboratory diagnosis like BP, FBS, PBS, 2D -ECHO. Statistical analysis was done by using chi square test a p-value of <0.001indicating significance.

Results: The study population consisted predominantly of males (69.09%), with the highest prevalence in the 42–51 age group (30.9%). HF Class 2 was the most common (57.7%). A significant proportion (71.8%) had diabetes, and 90% had hypertension. Post-treatment, improvements were observed in glycemic control, with 76.25% of patients having fasting blood sugar levels between 100–150 mg/dL. Notably, EF increased, with the proportion of patients having an EF >50% rising from 19.09% to 30% after treatment.

Conclusion: SGLT2 inhibitors enhance cardiac function and glucose control in type 2 diabetes patients with heart failure. It rose left ventricular ejection fraction and improved FBS and PBS levels, showing twin cardio-metabolic benefits. Socioeconomic and lifestyle variables such as city residence and alcohol consumption can affect progression of the disease. In total, SGLT2 inhibitors decrease hospitalization, cardiovascular death, and enhance real-world patient outcomes.

Keywords: SGLT2 Inhibitors , Heart failure, Diabetes Mellitus , Ejection Fraction